

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Henriette GOURDEAU et al.

Group: 1614

Serial No.: 10/824,563

Examiner: Unassigned

Filed: April 15, 2004

VIA FACSIMILE: 703-746-9195

For: METHODS OF TREATING LEUKEMIA

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

According to the formal Filing Receipt (copy attached) and the stamped postcard with the correct docket number attached, please make the corrections listed below:


Atty. Docket No.:

Please change the Attorney Docket No. from [PHARMA 100 D1] to read -- PHARMA 100 D2--

REMARKS

A copy of our transmittal letter is attached. It is believed that no fee is required since these are PTO errors. Accordingly, Applicants courteously request a corrected filing receipt.

Respectfully submitted,

  
Orion P. Bentley, Reg. No. 32,542  
Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO  
& BRANIGAN, P.C.  
Arlington Courthouse Plaza I  
2200 Clarendon Blvd. Suite 1400  
Arlington, Virginia 22201  
Telephone: (703)243-6333  
Facsimile: (703) 243-6410

Attorney Docket No.: PHARMA-100-D2

Date August 17, 2004

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Name: R. Taylor  
Signature: R. Taylor  
Date: 8-17-04



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: P.O. Box 1500, Arlington, VA 22201  
 Attention: Mr. [Name] 1-800-786-9899


APPL NO	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/824,563	04/15/2004	1614	1130	PHARMA 100 BT D2		40	3

24999

MILLEN, WHITE, ZELANO & BRANIGAN, PC  
 2200 CLARENDON BLVD  
 SUITE 1400  
 ARLINGTON, VA 22201

CONFIRMATION NO. 6418

## FILING RECEIPT



\*OC00000001306363\*

Date Mailed: 06/24/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Hennette Gourdeau, Montreal, CANADA,  
 Francis J. Giles, Houston, TX;

## Assignment For Published Patent Application

BioChem Pharma Inc., Laval, CANADA;

## Domestic Priority data as claimed by applicant

This application is a DIV of 09/536,459 03/28/2000 PAT 6,630,480  
 which claims benefit of 60/126,734 03/29/1999  
 and claims benefit of 60/126,813 03/30/1999

## Foreign Applications

If Required, Foreign Filing License Granted: 06/24/2004

Projected Publication Date: 09/30/2004

Non-Publication Request: No

Early Publication Request: No

*Handwritten signature and date:*  
 06/28/04

## Title

Methods of treating leukemia

## Preliminary Class

514

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 12.1-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)), the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

APPLICANT(S) :Henriette GOURDEAU et al.

FILED : April 15, 2004

TITLE :METHODS OF TREATING LEUKEMIA

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. DOCKET NO. PHARMA 100 D2

SERIAL NO.

FILED UNDER RULE 53(f)

☐ YES ☒ NO

Initials BPH/III

17302 U.S. PTO  
10/824563



*Diff*  
*4/21/04*  
*[Signature]*